FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FOREST LABORATORIES INC

2. Date of Event Requiring Statement (MM/DD/YYYY)
2/22/2011 

3. Issuer Name and Ticker or Trading Symbol

CLINICAL DATA INC [CLDA]

(Last)        (First)        (Middle)

909 THIRD AVENUE, 

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            ___ X ___ 10% Owner
_____ Officer (give title below)          _____ Other (specify below)

(Street)

NEW YORK, NY 10022       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock   0   (1) (2) I   (1) (2) See Footnotes   (1) (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(MM/DD/YYYY) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
2017 Convertible Notes   2/25/2009   (3) 2/25/2017   (4) Common Stock   0   (1) (2) $8.1825   I   (1) (2) See Footnotes   (1) (2)
2005 Warrants   11/17/2005   5/17/2011   Common Stock   0   (1) (2) $15.60   I   (1) (2) See Footnotes   (1) (2)
2008 Warrants   9/26/2008   3/26/2014   Common Stock   0   (1) (2) $16.44   I   (1) (2) See Footnotes   (1) (2)
2009 Warrants   2/25/2009   8/25/2014   Common Stock   0   (1) (2) $8.120   I   (1) (2) See Footnotes   (1) (2)
2009 Warrants   2/25/2009   8/25/2014   Common Stock   0   (1) (2) $9.744   I   (1) (2) See Footnotes   (1) (2)

Explanation of Responses:
( 1)  Solely for purposes of determining whether a person is a beneficial owner of more than ten percent (a "ten percent owner") of any class of equity securities registered pursuant to section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Rule 16a-1 under the Exchange Act ("Rule 16a-1") provides that the term "beneficial owner" shall mean any person who is deemed a beneficial owner pursuant to Section 13(d) of the Exchange Act and the rules thereunder. Rule 13d-3 under the Exchange Act ("Rule 13d-3"), in turn, provides that a person will be deemed to beneficially own all securities over which such person (i) has voting or investment control or (ii) may acquire voting or investment control within 60 days of the date of determination. (Continued in Footnote 2)
( 2)  For reporting purposes, however, Rule 16a-2 under the Exchange Act ("Rule 16a-2") provides that a person is only deemed to be the beneficial owner of securities if that person has or shares the opportunity, directly or indirectly, to profit or share in any profit derived from a transaction in such securities (a "pecuniary interest"). However, none of the Forest Entities have any pecuniary interest in the Subject Securities (as defined below) and therefore, in accordance with Rule 16a-2, they are not deemed to beneficially own any of the Subject Securities.
( 3)  The 2017 Convertible Notes may be repaid at any time upon 90 days prior notice.
( 4)  The final maturity date of the 2017 Convertible Notes is February 25, 2017.

Remarks:
This form is filed on behalf of Forest Laboratories, Inc. ("Forest"), FL Holding C.V. ("FL Holding"), FLI International LLC ("FLI International") and Magnolia Acquisition Corp. ("Magnolia", and together with Forest, FL Holding and FLI International, the "Forest Entities" and each a "Forest Entity"), all of which are filing as members of a 10% owner group. Forest is the direct parent of FL Holding, and the indirect parent of FLI International and Magnolia. FL Holding is the parent of Magnolia, and FLI International is the general partner of FL Holding. The principal business address of Forest is Forest Laboratories, Inc., 909 Third Avenue, New York, New York 10019. The principal business address of each of FLI International and Magnolia is c/o Forest Laboratories, Inc., 909 Third Avenue, New York, New York 10019. The principal business address of FL Holding is Cox Hallett Wilkson, Cumberland House, 1 Victoria Street, 9th Floor, Hamilton, Bermuda HM11.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
FOREST LABORATORIES INC
909 THIRD AVENUE
NEW YORK, NY 10022
X

FL Holding C.V.
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022

Manager
FLI International, LLC
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022

Vice President
Magnolia Acquisition Corp.
C/O FOREST LABORATORIES, INC.
909 THIRD AVENUE
NEW YORK, NY 10022

Vice President

Signatures
/s/ Herschel S. Weinstein, Vice President and General Counsel of Forest Laboratories, Inc. 3/4/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Clinical Data (NASDAQ:CLDA)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Clinical Data
Grafico Azioni Clinical Data (NASDAQ:CLDA)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Clinical Data